Disclosure Of Interests In Other Entities [Text Block]

Transgene - Filing #6250839

Concept	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	As at 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2022-12-31
Disclosure of interests in other entities [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of interests in subsidiaries [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of subsidiaries [text block]	—	Principes de consolidation	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of subsidiaries [abstract]
Disclosure of subsidiaries [line items]
Current assets	—	—	—	—	20 668 EUR	—	—	—	—	—	—	—	17 984 EUR	—	—	—	—
Non-current assets	—	—	—	—	21 506 EUR	—	—	—	—	—	—	—	27 233 EUR	—	—	—	—
Current liabilities	—	—	—	—	13 984 EUR	—	—	—	—	—	—	—	10 042 EUR	—	—	—	—
Non-current liabilities	—	—	—	—	12 986 EUR	—	—	—	—	—	—	—	19 563 EUR	—	—	—	—
Profit (loss)	- EUR	33 971 EUR	- EUR	33 971 EUR	—	- EUR	- EUR	- EUR	- EUR	22 328 EUR	- EUR	22 328 EUR	—	- EUR	- EUR	- EUR	—
Comprehensive income	- EUR	33 775 EUR	- EUR	33 971 EUR	—	- EUR	- EUR	196,000 EUR	- EUR	22 520 EUR	- EUR	22 328 EUR	—	- EUR	- EUR	192,000 EUR	—
Disclosure of interests in associates [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of associates [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of associates [abstract]
Disclosure of associates [line items]
Other comprehensive income	—	196,000 EUR	—	—	—	—	—	—	—	192,000 EUR	—	—	—	—	—	—	—
Disclosure of interests in joint arrangements [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of joint operations [text block]	—	La Société codéveloppe certains produits avec des partenaires, notamment avec les sociétés NEC et BioInvent. Dans ce cadre, les sociétés refacturent leurs contributions respectives au projet concerné, en fonction de modalités prévues contractuellement. La Société prend en compte ces refacturations de produits/charges en diminution/augmentation de ses dépenses de recherche et développement, conformément à IFRS 11.	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of joint ventures [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of joint ventures [abstract]
Disclosure of joint ventures [line items]
Cash and cash equivalents	—	—	—	—	16 670 EUR	—	—	—	—	—	—	—	15 666 EUR	—	—	—	4 403 EUR
Tax expense (income)	—	- EUR	—	—	—	—	—	—	—	- EUR	—	—	—	—	—	—	—